菌移植治疗腹泻型肠易激综合征的疗效及安全性研究  

Efficacy and safety of fecal microbiota transplantation in the treatment of diarrhea-predominant irritable bowel syndrome

作　　者：彭慧芸 袁瑜[2] 谢文瑞[2] 吴礼浩[2] PENG Huiyun;YUAN Yu;XIE Wenrui;WU Lihao(Department of Gastroenterology,People's Hospital of Xinxing County,Xingxing 527400,China;Department of Gastroenterology,The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou 510080,China)

机构地区：[1]新兴县人民医院消化内科,新兴527400 [2]广东药科大学附属第一医院消化内科,广州510080

出　　处：《广州医药》2019年第6期39-42,共4页Guangzhou Medical Journal

摘　　要：目的观察粪菌移植治疗腹泻型肠易激综合征的临床疗效及安全性。方法以2017年12月—2019年1月期间,广东药科大学附属第一医院收治的67例腹泻型肠易激综合征患者作为研究对象,进行回顾性分析。将患者分为2组,对照组36例,观察组31例。对照组患者采用曲美布汀和复方乳酸杆菌治疗,观察组患者采用粪菌移植治疗。3个月后,对比患者治疗前后每日排便次数、Bristol粪便评分、肠易激综合征生命质量(IBS-QOL)评分、焦虑自评量表(SAS)评分和抑郁自评量表(SDS)评分。同时记录患者治疗期间的不良反应。结果经过治疗后,观察3个月,所有患者每日排便次数、Bristol粪便评分、IBS-QOL评分、SAS评分、SDS评分均较治疗前有所下降,差异均有统计学意义(P<0.05)。观察组患者上述指标均低于对照组,差异均有统计学意义(P<0.05)。两组患者治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论粪菌移植治疗腹泻型肠易激综合征,具有确切的治疗效果,对于减少每日排便次数,改善粪便性状,缓解患者焦虑、抑郁状态具有积极的意义,并且具有较为可靠的安全性。Objective To observe the clinical efficacy and safety of fecal microbiota transplantation in the treatment of diarrhea-type irritable bowel syndrome.Methods From December 2017 to January 2019,a retrospective analysis of 67 patients with diarrhea-type irritable bowel syndrome admitted to the First Affiliated Hospital of Guangdong Pharmaceutical University were selected as subjects.The patients were divided into 2 groups,36 in the control group and 31 in the observation group.The patients in the control group were treated with trimebutine and compound lactobacilli.The patients in the observation group were treated with fecal microbiota transplantation.Three months later,the number of daily bowel,Bristol fecal scores,irritable bowel syndrome quality of life(IBS-QOL)score,anxiety self-rating scale(SAS)score,and depression self-rating scale(SDS)score were compared before and after treatment.At the same time,the adverse reactions during the treatment of the patients were recorded.Results After treatment,observation for 3 months,the number of daily bowel,Bristol stool score,IBS-QOL score,SAS score and SDS score of all patients were lower than those before treatment,and the difference was statistically significant(P<0.05).The above indexes of the observation group were lower than the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion The treatment of diarrhea-type irritable bowel syndrome with fecal microbiota transplantation has a definite therapeutic effect.It has positive significance for reducing the number of daily bowel,improving fecal traits,relieving anxiety and depression,and has relatively reliable safety.

关 键 词：粪菌移植 肠易激综合征 腹泻 生活质量 焦虑 抑郁 

分 类 号：R47[医药卫生—护理学]